CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients
L Arnaud, B Hervier, A Néel… - Blood, The Journal …, 2011 - ashpublications.org
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans histiocytosis, with
noncodified therapeutic management and high mortality. No treatment has yet been shown to …
noncodified therapeutic management and high mortality. No treatment has yet been shown to …
[HTML][HTML] Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors
…, P Gicquel, D Boutoille, F Raffi, A Néel… - Journal of thrombosis …, 2020 - Springer
Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic
events are debated and highly heterogeneous. The objective was to determine incidence and …
events are debated and highly heterogeneous. The objective was to determine incidence and …
Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody–associated vasculitis: a randomized trial
…, M Samson, B Bonnotte, A Néel… - Annals of internal …, 2020 - acpjournals.org
Background: Biannual rituximab infusions over 18 months effectively maintain remission
after a “standard” remission induction regimen for patients with antineutrophil cytoplasmic …
after a “standard” remission induction regimen for patients with antineutrophil cytoplasmic …
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation
…, F Charlotte, J Donadieu, A Néel… - Blood, The Journal …, 2014 - ashpublications.org
Histiocytoses are a group of heterogeneous diseases that mostly comprise Langerhans cell
histiocytosis (LCH) and non-LCH. The association of LCH with non-LCH is exceptional. We …
histiocytosis (LCH) and non-LCH. The association of LCH with non-LCH is exceptional. We …
Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients
…, T Mirault, JE Kahn, M Lambert, J Sibilia, A Néel… - Circulation, 2015 - Am Heart Assoc
Background— The goal of this work was to assess the safety and efficacy of biologics (ie,
tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis. …
tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis. …
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare histiocytic
disorders induced by somatic mutation of MAPK pathway genes. BRAF V600E mutation is …
disorders induced by somatic mutation of MAPK pathway genes. BRAF V600E mutation is …
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients
P Charles, A Neel, N Tieulie, A Hot, G Pugnet… - …, 2014 - academic.oup.com
Objectives. Rituximab has been shown to induce remission of ANCA-associated vasculitides
(AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for …
(AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for …
Adding azathioprine to remission‐induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg‐Strauss), microscopic polyangiitis, or polyarteritis …
…, G Baron, T Quémeneur, A Néel… - Arthritis & …, 2017 - Wiley Online Library
Objective In most patients with nonsevere systemic necrotizing vasculitides ( SNV s), remission
is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. …
is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. …
Primary angiitis of the central nervous system: description of the first fifty‐two adults enrolled in the French cohort of patients with primary vasculitis of the central …
…, C Arquizan, B Bienvenu, A Néel… - Arthritis & …, 2014 - Wiley Online Library
Objective To describe characteristics and outcomes of a multicenter cohort of patients diagnosed
as having primary angiitis of the central nervous system (PACNS). Methods In 2010, we …
as having primary angiitis of the central nervous system (PACNS). Methods In 2010, we …
Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study
A Néel, B Henry, S Barbarot, A Masseau, F Perrin… - Autoimmunity …, 2014 - Elsevier
The aim of this study is to assess the long-term effectiveness and safety of IL1Ra in Schnitzler
syndrome (SchS). Between 2010 and 2012, we performed a nationwide survey among …
syndrome (SchS). Between 2010 and 2012, we performed a nationwide survey among …